Atai Beckley N.V.ATAIEarnings & Financial Report
Nasdaq
atai Life Sciences is a pharmaceutical company that is developing psychedelics, other hallucinogens, entactogens, and related drugs for treatment of psychiatric conditions. It was founded in 2018 and is headquartered in Berlin, Germany.
NextMar 31, 2026
ATAI Q3 2025 Key Financial Metrics
Revenue
$749.0K
Gross Profit
N/A
Operating Profit
$-28.4M
Net Profit
$-61.1M
Gross Margin
N/A
Operating Margin
-3796.5%
Net Margin
-8154.1%
YoY Growth
1772.5%
EPS
$-0.28
Financial Flow
Atai Beckley N.V. Q3 2025 Financial Summary
Atai Beckley N.V. reported revenue of $749.0K for Q3 2025, with a net profit of $-61.1M (-8154.1% margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $749.0K |
|---|---|
| Net Profit | $-61.1M |
| Gross Margin | N/A |
| Operating Margin | -3796.5% |
| Report Period | Q3 2025 |
Atai Beckley N.V. Annual Revenue by Year
Atai Beckley N.V. annual revenue history includes year-by-year totals (for example, 2024 revenue was $308.0K).
| Year | Annual Revenue |
|---|---|
| 2024 | $308.0K |
| 2023 | $314.0K |
| 2022 | $233.0K |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $18000 | $0 | $273000 | $40000 | $-5000 | $1.6M | $719000 | $749000 |
| YoY Growth | -53.8% | N/A | 58.7% | -54.0% | -127.8% | N/A | 163.4% | 1772.5% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $293.5M | $269.1M | $215.8M | $197.5M | $159.4M | $195.8M | $189.2M | $239.8M |
| Liabilities | $49.2M | $45.9M | $47.2M | $51.2M | $42.8M | $43.5M | $45.3M | $79.9M |
| Equity | $243.0M | $222.5M | $167.9M | $145.7M | $116.3M | $152.1M | $143.7M | $159.8M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-22.0M | $-22.6M | $-16.2M | $-19.3M | $-24.3M | $-17.8M | $-14.1M | $-23.3M |